Syndecan-4 Enhances Therapeutic Angiogenesis after Hind Limb Ischemia in Mice with Type 2 Diabetes

被引：26
作者：
Das, Subhamoy [1 ]
Monteforte, Anthony J. [1 ]
Singh, Gunjan [1 ]
Majid, Marjan [1 ]
Sherman, Michael B. [2 ]
Dunn, Andrew K. [1 ]
Baker, Aaron B. [1 ,3 ,4 ,5 ]
机构：
[1] Univ Texas Austin, Dept Biomed Engn, Austin, TX USA
[2] Univ Texas Med Branch, Sealy Ctr Struct Biol & Mol Biophys, Galveston, TX 77555 USA
[3] Univ Texas Austin, Inst Cellular & Mol Biol, Austin, TX 78712 USA
[4] Univ Texas Austin, Inst Computat Engn & Sci, Austin, TX 78712 USA
[5] Univ Texas Austin, Inst Biomat Drug Delivery & Regenerat Med, Austin, TX 78712 USA
来源：
ADVANCED HEALTHCARE MATERIALS | 2016年 / 5卷 / 09期
关键词：
PERIPHERAL ARTERIAL-DISEASE; FIBROBLAST GROWTH FACTOR-2; INTERMITTENT CLAUDICATION; DOUBLE-BLIND; TRIAL; PLACEBO;
D O I：
10.1002/adhm.201500993
中图分类号：
R318 [生物医学工程];
学科分类号：
0831 ;
摘要：
Delivering syndecan-4 with FGF-2 improves the effectiveness of FGF-2 therapy for ischemia in the diabetic disease state. The syndecan-4 proteoliposomes significantly enhance in vitro tubule formation as well as blood perfusion and vessel density in the ischemic hind limbs of diseased ob/ob mice. Syndecan-4 therapy also induces a marked immunomodulation in the tissues, increasing the polarization of macrophages toward the M2 phenotype. © 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
引用
收藏
页码：1008 / 1013
页数：6
相关论文
共 20 条
  • [1] Economic Costs of Diabetes in the U.S. in 2012
    Yang W.
    Dall T.M.
    Halder P.
    Gallo P.
    Kowal S.L.
    Hogan P.F.
    Petersen M.
    [J]. DIABETES CARE, 2013, 36 (04) : 1033 - 1046
  • [2] Bruhn-Olszewska B, 2012, ACTA BIOCHIM POL, V59, P507
  • [3] Overcoming disease-induced growth factor resistance in therapeutic angiogenesis using recombinant co-receptors delivered by a liposomal system
    Das, Subhamoy
    Singh, Gunjan
    Baker, Aaron B.
    [J]. BIOMATERIALS, 2014, 35 (01) : 196 - 205
  • [4] Syndecan-4 signaling at a glance
    Elfenbein, Arye
    Simons, Michael
    [J]. JOURNAL OF CELL SCIENCE, 2013, 126 (17) : 3799 - 3804
  • [5] Syndecan-4 proteoliposomes enhance fibroblast growth factor-2 (FGF-2)-induced proliferation, migration, and neovascularization of ischemic muscle
    Jang, Eugene
    Albadawi, Hassan
    Watkins, Michael T.
    Edelman, Elazer R.
    Baker, Aaron B.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (05) : 1679 - 1684
  • [6] Inflammation and wound healing: the role of the macrophage
    Koh, Timothy J.
    DiPietro, Luisa Ann
    [J]. EXPERT REVIEWS IN MOLECULAR MEDICINE, 2011, 13 : e23
  • [7] Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: A double-blind randomized trial
    Kusumanto, Y. H.
    Van Weel, V.
    Mulder, N. H.
    Smit, A. J.
    Van den Dungen, J. J. A. M.
    Hooymans, J. M. M.
    Sluiter, W. J.
    Tio, R. A.
    Quax, P. H. A.
    Gans, R. O. B.
    Dullaart, R. P. F.
    Hospers, G. A. P.
    [J]. HUMAN GENE THERAPY, 2006, 17 (06) : 683 - 691
  • [8] Basic fibroblast growth factor in patients with intermittent claudication: Results of a phase I trial
    Lazarous, DF
    Unger, EF
    Epstein, SE
    Stine, A
    Arevalo, JL
    Chew, EY
    Quyyumi, AA
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (04) : 1239 - 1244
  • [9] Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial
    Lederman, RJ
    Mendelsohn, FO
    Anderson, RD
    Saucedo, JF
    Tenaglia, AN
    Hermiller, JB
    Hillegass, WB
    Rocha-Singh, K
    Moon, TE
    Whitehouse, MJ
    Annex, BH
    [J]. LANCET, 2002, 359 (9323) : 2053 - 2058
  • [10] Peripheral arterial disease in patients with diabetes
    Marso, SP
    Hiatt, WR
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (05) : 921 - 929
12